Cover Image
市場調查報告書

纖維肉瘤 : 開發平台分析

Fibrosarcoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 321906
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
纖維肉瘤 : 開發平台分析 Fibrosarcoma - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 64 Pages
簡介

纖維肉瘤是由纖維性結締組織發病的惡性腫瘤,症狀有疼痛、腫、局部發熱、血管擴張痛、骨骼肥大、病理性骨折、神經及血管的變化等。

本報告提供纖維肉瘤的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

纖維肉瘤概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/實驗室

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/實驗室

開發治療藥的企業

  • Advanced Proteome Therapeutics Corporation
  • Advenchen Laboratories, LLC
  • Elsalys Biotech SAS
  • Novartis AG
  • Plexxikon Inc.
  • Rigontec GmbH
  • 大日本住友製藥

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AL-3818
  • APC-103
  • DSR-6434
  • everolimus
  • ImOl-100
  • KRA-0008
  • LK-3
  • MAT-303
  • PLX-7486
  • SEN-461

最新的開發平台資訊

開發暫停中的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8374IDB

Summary

Global Markets Direct's, 'Fibrosarcoma - Pipeline Review, H2 2016', provides an overview of the Fibrosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fibrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Fibrosarcoma
  • The report reviews pipeline therapeutics for Fibrosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Fibrosarcoma therapeutics and enlists all their major and minor projects
  • The report assesses Fibrosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Fibrosarcoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Fibrosarcoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibrosarcoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fibrosarcoma Overview
  • Therapeutics Development
    • Pipeline Products for Fibrosarcoma - Overview
    • Pipeline Products for Fibrosarcoma - Comparative Analysis
  • Fibrosarcoma - Therapeutics under Development by Companies
  • Fibrosarcoma - Therapeutics under Investigation by Universities/Institutes
  • Fibrosarcoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Fibrosarcoma - Products under Development by Companies
  • Fibrosarcoma - Products under Investigation by Universities/Institutes
  • Fibrosarcoma - Companies Involved in Therapeutics Development
    • Advanced Proteome Therapeutics Corporation
    • Advenchen Laboratories, LLC
    • Daiichi Sankyo Company, Limited
    • Elsalys Biotech SAS
    • Millennium Pharmaceuticals Inc
    • Novartis AG
    • Rigontec GmbH
    • Sumitomo Dainippon Pharma Co., Ltd.
  • Fibrosarcoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AL-3818 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APC-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSR-6434 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ImOl-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LK-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAT-303 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-7486 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sapanisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEN-461 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SOM-0777 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fibrosarcoma - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Fibrosarcoma, H2 2016
  • Number of Products under Development for Fibrosarcoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Fibrosarcoma - Pipeline by Advanced Proteome Therapeutics Corporation, H2 2016
  • Fibrosarcoma - Pipeline by Advenchen Laboratories, LLC, H2 2016
  • Fibrosarcoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Fibrosarcoma - Pipeline by Elsalys Biotech SAS, H2 2016
  • Fibrosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Fibrosarcoma - Pipeline by Novartis AG, H2 2016
  • Fibrosarcoma - Pipeline by Rigontec GmbH, H2 2016
  • Fibrosarcoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Fibrosarcoma - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Fibrosarcoma, H2 2016
  • Number of Products under Development for Fibrosarcoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top